Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385778932> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4385778932 endingPage "118" @default.
- W4385778932 startingPage "112" @default.
- W4385778932 abstract "It was to explore the effect of neoadjuvant therapy (NAT) on serum-related indicators and prognosis of patients with locally advanced esophageal cancer (EC). 400 EC patients were grouped as controls (295 cases, radical EC resection alone) and research group (105 cases, NAT plus radical EC resection). The levels of serum carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), programmed death-1 (PD-1), PD-2, transforming growth factor-β1 (TGF-β1), and squamous cell carcinoma (SCC) antigen were detected before and after treatment. The follow-up lasted for 3 years. The quality of life (QoL) was evaluated by QLQ-OES24. The recurrence rate, recurrence time, overall survival rate (SR), disease-free SR, and complication rate were compared. Compared with controls, the levels of serum CA19-9, CEA, CYFRA21-1, PD-1, PD-2, TGF-β1, and SCC were decreased, the QoL score was increased 3 years post-treatment, and the recurrence time was prolonged in the research group (P<0.05). The R0 resection rate, recurrence rate, 3-year overall SR, and disease-free SR of the two groups were 67.12% vs 85.71%, 21.36% vs 6.67%, 56.27% vs 77.14%, 29.83% vs 45.71%, respectively (P<0.05). The complication rates of the two groups were 32.54% and 29.52%, respectively (P>0.05). NAT plus radical resection of EC can effectively reduce the level of serum oncology markers in patients with locally advanced EC, reduce the postoperative recurrence rate, improve QoL and SR, and has high safety." @default.
- W4385778932 created "2023-08-13" @default.
- W4385778932 creator A5029361794 @default.
- W4385778932 creator A5036077214 @default.
- W4385778932 creator A5045825493 @default.
- W4385778932 creator A5056445856 @default.
- W4385778932 creator A5064108264 @default.
- W4385778932 creator A5076857313 @default.
- W4385778932 creator A5081675343 @default.
- W4385778932 date "2023-05-31" @default.
- W4385778932 modified "2023-09-25" @default.
- W4385778932 title "Effect of neoadjuvant therapy on serum transforming growth factor-β, squamous cell carcinoma associated antigen, and prognosis in patients with locally advanced esophageal cancer" @default.
- W4385778932 doi "https://doi.org/10.14715/cmb/2023.69.5.18" @default.
- W4385778932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37571892" @default.
- W4385778932 hasPublicationYear "2023" @default.
- W4385778932 type Work @default.
- W4385778932 citedByCount "0" @default.
- W4385778932 crossrefType "journal-article" @default.
- W4385778932 hasAuthorship W4385778932A5029361794 @default.
- W4385778932 hasAuthorship W4385778932A5036077214 @default.
- W4385778932 hasAuthorship W4385778932A5045825493 @default.
- W4385778932 hasAuthorship W4385778932A5056445856 @default.
- W4385778932 hasAuthorship W4385778932A5064108264 @default.
- W4385778932 hasAuthorship W4385778932A5076857313 @default.
- W4385778932 hasAuthorship W4385778932A5081675343 @default.
- W4385778932 hasBestOaLocation W43857789321 @default.
- W4385778932 hasConcept C118131993 @default.
- W4385778932 hasConcept C121608353 @default.
- W4385778932 hasConcept C126322002 @default.
- W4385778932 hasConcept C126894567 @default.
- W4385778932 hasConcept C143998085 @default.
- W4385778932 hasConcept C147483822 @default.
- W4385778932 hasConcept C203014093 @default.
- W4385778932 hasConcept C2776283816 @default.
- W4385778932 hasConcept C2777387746 @default.
- W4385778932 hasConcept C2778292576 @default.
- W4385778932 hasConcept C2779742542 @default.
- W4385778932 hasConcept C2781447364 @default.
- W4385778932 hasConcept C530470458 @default.
- W4385778932 hasConcept C71924100 @default.
- W4385778932 hasConcept C81182388 @default.
- W4385778932 hasConcept C90924648 @default.
- W4385778932 hasConceptScore W4385778932C118131993 @default.
- W4385778932 hasConceptScore W4385778932C121608353 @default.
- W4385778932 hasConceptScore W4385778932C126322002 @default.
- W4385778932 hasConceptScore W4385778932C126894567 @default.
- W4385778932 hasConceptScore W4385778932C143998085 @default.
- W4385778932 hasConceptScore W4385778932C147483822 @default.
- W4385778932 hasConceptScore W4385778932C203014093 @default.
- W4385778932 hasConceptScore W4385778932C2776283816 @default.
- W4385778932 hasConceptScore W4385778932C2777387746 @default.
- W4385778932 hasConceptScore W4385778932C2778292576 @default.
- W4385778932 hasConceptScore W4385778932C2779742542 @default.
- W4385778932 hasConceptScore W4385778932C2781447364 @default.
- W4385778932 hasConceptScore W4385778932C530470458 @default.
- W4385778932 hasConceptScore W4385778932C71924100 @default.
- W4385778932 hasConceptScore W4385778932C81182388 @default.
- W4385778932 hasConceptScore W4385778932C90924648 @default.
- W4385778932 hasIssue "5" @default.
- W4385778932 hasLocation W43857789321 @default.
- W4385778932 hasLocation W43857789322 @default.
- W4385778932 hasOpenAccess W4385778932 @default.
- W4385778932 hasPrimaryLocation W43857789321 @default.
- W4385778932 hasRelatedWork W2014842418 @default.
- W4385778932 hasRelatedWork W2040350626 @default.
- W4385778932 hasRelatedWork W2249625608 @default.
- W4385778932 hasRelatedWork W2351696676 @default.
- W4385778932 hasRelatedWork W2381496852 @default.
- W4385778932 hasRelatedWork W2388622596 @default.
- W4385778932 hasRelatedWork W2390259839 @default.
- W4385778932 hasRelatedWork W2400288300 @default.
- W4385778932 hasRelatedWork W2811042001 @default.
- W4385778932 hasRelatedWork W3030915696 @default.
- W4385778932 hasVolume "69" @default.
- W4385778932 isParatext "false" @default.
- W4385778932 isRetracted "false" @default.
- W4385778932 workType "article" @default.